Acute, proximal DVT of the lower extremity Deep vein thrombosis
Conditions
Interventions
Treatment with Venoruton 500mg film-coated tablets oral twice daily for eight weeks after DVT
Sponsors
Maastricht University Medical Center (MUMC+)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult ; Objectively confirmed DVT of lower extremity by DUS; Proximal localisation of DVT; Acute onset of DVT (symptoms for = 7 days at presentation); Willing and able to give written consent
Exclusion criteria
Exclusion criteria: Previous DVT; Bilateral DVT; Pre-existent chronic venous insufficiency; Active malignancy or inflammatory disease; Pregnancy; Indication for therapeutic thrombolysis; Contra-indication for DOAC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of RVO, defined as a vein diameter =2mm on DUS during full compression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Circulating biomarkers levels of inflammation, cell adhesion and remodeling; Severity of PTS-characterizing clinical signs and symptoms (Villalta-scale + leg circumferences); QoL scores (VEINS-QOL/Sym, SF-36, EQ-5D). Additional assessments are medication adherence (MMAS-8), compliance to ECT, and pill count of Venoruton (if applicable) and DOAC. | — |
Contacts
Public ContactAaron F.J. Iding
Maastricht University Medical Center (MUMC+)
Outcome results
None listed